文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

右美托咪定预防儿科重症监护病房戒断综合征的有效性和安全性:适应性、多中心、随机、双盲、安慰剂对照、非营利临床试验方案

Efficacy and safety of dexmedetomidine for prevention of withdrawal syndrome in the pediatric intensive care unit: protocol for an adaptive, multicenter, randomized, double-blind, placebo-controlled, non-profit clinical trial.
PubMed 文献 · Trials · 2019-12-11

本研究为适应性、多中心、随机、双盲、安慰剂对照试验,计划纳入154例接受持续静脉镇痛镇静治疗至少5天且准备撤药的18岁以下PICU患者,评估右美托咪定减少戒断综合征发生率的效果及安全性,主要终点为与安慰剂相比WS发生率的降低。

要点

  • 右美托咪定可能减少PICU镇痛镇静撤药期间戒断综合征的发生。
  • 试验采用适应性、多中心、随机、双盲、安慰剂对照设计。
  • 计划样本量每组77例,总样本量154例,检验效能90%。

核心结论

  • 该试验旨在明确评估右美托咪定减少镇痛镇静撤药期间戒断综合征发生的有效性,并提供其安全性特征的独特见解。

研究设计与样本

  • 适应性、多中心、随机、双盲、安慰剂对照、非营利临床试验。
  • 纳入年龄小于18岁、接受持续静脉镇痛镇静治疗至少5天且临床状况允许撤药的患者。
  • 随机分配至治疗A(右美托咪定)或治疗B(安慰剂)。
  • 样本量以保证90%检验效能计算为每组77例,总样本量154例。

关键数值与推荐

  • 右美托咪定在镇痛镇静撤药前24小时开始,剂量为0.4 μg/kg/h,每小时增加0.2 μg/kg/h至0.8 μg/kg/h;新生儿为0.2 μg/kg/h,每小时增加0.1 μg/kg/h至0.4 μg/kg/h,并持续整个撤药期。
  • 主要终点为与安慰剂相比,右美托咪定组戒断综合征发生率的降低。
  • 安全性通过收集任何可能相关的不良事件进行评估。

临床怎么用

  • 若试验证实有效,右美托咪定可用于PICU镇痛镇静撤药期间预防戒断综合征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prolonged treatment with analgesic and sedative drugs in the pediatric intensive care unit (PICU) may lead to undesirable effects such as dependence and tolerance. Moreover, during analgosedation weaning, patients may develop clinical signs of withdrawal, known as withdrawal syndrome (WS). Some studies indicate that dexmedetomidine, a selective α2-adrenoceptor agonist, may be useful to prevent WS, but no clear evidence supports these data. The aims of the present study are to evaluate the efficacy of dexmedetomidine in reducing the occurrence of WS during analgosedation weaning, and to clearly assess its safety. METHODS: We will perform an adaptive, multicenter, randomized, double-blind, placebo-controlled trial. Patients aged < 18 years receiving continuous intravenous analgosedation treatment for at least 5 days and presenting with clinical conditions that allow analgosedation weaning will be randomly assigned to treatment A (dexmedetomidine) or treatment B (placebo). The treatment will be started 24 h before the analgosedation weaning at 0.4 μg/kg/h, increased by 0.2 μg/kg/h per hour up to 0.8 μg/kg/h (neonate: 0.2 μg/kg/h, increased by 0.1 μg/kg/h per hour up to 0.4 μg/kg/h) and continued throughout the whole weaning time. The primary endpoint is the efficacy of the treatment, defined by the reduction in the WS rate among patients treated with dexmedetomidine compared with patients treated with placebo. Safety will be assessed by collecting any potentially related adverse event. The sample size assuring a power of 90% is 77 patients for each group (total N = 154 patients). The study was approved by the Ethics Committee of the University-Hospital S.Orsola-Malpighi of Bologna on 22 March 2017. DISCUSSION: The present trial will allow us to clearly assess the efficacy of dexmedetomidine in reducing the occurrence of WS during weaning from analgosedation drugs. In addition, the study will provide a unique insight into the safety profile of dexmedetomidine. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03645603. Registered on 24 August 2018. EudraCT, 2015-002114-80. Retrospectively registered on 2 January 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mondardini MC, Sperotto F, Daverio M, et al. Efficacy and safety of dexmedetomidine for prevention of withdrawal syndrome in the pediatric intensive care unit: protocol for an adaptive, multicenter, randomized, double-blind, placebo-controlled, non-profit clinical trial. Trials. 2019. PMID: 31829274. doi:10.1186/s13063-019-3793-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。